
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
enGene Therapeutics is a promising investment opportunity due to the convenience and safety of their gene therapy, detalimogene, for treating Non-Muscle Invasive Bladder Cancer (NMIBC). The upcoming 12-month CR readout from Cohort 1 and polidocanol bladder rinse cohort data serve as critical milestones for the company, along with potential BLA filing initiation and approval decision in 2027. While there are risks, such as R&D setbacks and competition, the potential upside for pipeline success and product sales make it a compelling investment choice. Financial data shows an increase in net loss, primarily due to higher expenses related to ongoing clinical trials and preparation for BLA submission.
Bears say
enGene Therapeutics is facing a number of challenges that could potentially hinder the success and marketability of their lead product, detalimogene voraplasmid. The recent clinical data from the ongoing LEGEND Phase 2 trial has shown a decline in efficacy compared to previous interim analyses, causing concern among investors. Additionally, the company has had to make significant workforce reductions and has put enrollment plans on hold, potentially delaying commercialization. While detalimogene has unique advantages in its mode of administration and safety profile, it falls short of contemporary benchmarks and may struggle to gain a significant share of the increasingly competitive NMIBC market.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares